Regulation of Tumor Oxygenation by BACH1 in Breast Cancer

BACH1 在乳腺癌中对肿瘤氧合的调节

基本信息

  • 批准号:
    10693966
  • 负责人:
  • 金额:
    $ 39.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Triple negative breast cancer (TNBC), the most aggressive and metastatic subtype of breast cancer, is one of the major causes of cancer death in women. TNBC also has lower survival rates for primarily local cancers. Loss of hormone receptors and the lack of HER2 overexpression in TNBC limit treatments to cytotoxic therapies such as radiation, a key clinical strategy for 10-15% of breast cancer patients. Hypoxia is a major cause of resistance to radiotherapy, chemotherapy and even immunotherapy. Thus, identifying mechanisms to suppress the hypoxia stress response and increase the sensitivity of TNBC tumors to therapy remains a top clinical priority. Upon hypoxic stress, cancer cells initiate a transcriptional program that enables them to survive and migrate from an inhospitable microenvironment. While hypoxia-inducible factors (HIFs) are generally considered the main effectors, growing evidence suggests the hypoxia cellular response is much more complex and requires coordinated signaling with other stress response factors. One promising candidate is BACH1, a transcription factor that is induced by hypoxia and represses transcription of genes involved in heme oxidation and anti-oxidant production. Based on preliminary results, we now hypothesize that BACH1 is stabilized by hypoxia and functions as a key inducer of the cellular hypoxia response in TNBC cells leading to abnormal leaky vasculature that contributes to intratumoral hypoxia and radiation resistance. Specifically, we plan to: 1. Determine whether BACH1 is regulated by oxygen and induces a transcriptional hypoxic stress response in TNBC cells; 2. Determine whether BACH1 promotes angiogenesis, leaky vasculature and hypoxia in TNBC tumors; and 3. Determine whether BACH1 depletion sensitizes TNBC tumors to radiation. We propose that targeting BACH1 represents a unique strategy for increasing tumor oxygenation to improve the efficacy of cytotoxic, standard-of-care therapies such as radiation. Normalizing vasculature to suppress leakiness should also facilitate drug delivery to tumors. Since BACH1 can be targeted by an FDA approved drug either alone or in combination with HIF inhibitors, the proposed work could lead to a clinical trial in breast cancer and other cancer patients whose treatment involves radiation therapy.
三阴性乳腺癌(TNBC)是乳腺癌中最具侵袭性和转移性的亚型之一。 女性癌症死亡的主要原因。TNBC也有较低的存活率,主要是当地的 癌症。在TNBC中激素受体的丢失和HER2过表达的缺乏限制了治疗 放射等细胞毒性疗法是10%-15%的乳腺癌患者的关键临床策略。低氧 是抵抗放射治疗、化疗甚至免疫治疗的主要原因。因此,识别 抑制低氧应激反应和增加TNBC肿瘤对药物敏感性的机制 治疗仍然是临床上的首要任务。在低氧应激下,癌细胞启动转录程序, 使它们能够从不适宜居住的微环境中生存和迁徙。而低氧诱导因子 (HIF)通常被认为是主要的效应器,越来越多的证据表明,低氧细胞的反应是 要复杂得多,需要与其他应激反应因素协调信号。一件有希望的事 候选基因是BACH1,这是一种由低氧诱导并抑制基因转录的转录因子 参与血红素氧化和抗氧化剂的生产。根据初步结果,我们现在假设 BACH1受低氧稳定,是TNBC细胞低氧反应的关键诱导物 导致异常渗漏血管的细胞,导致肿瘤内缺氧和辐射 抵抗。具体来说,我们计划:1.确定BACH1是否受氧调节并诱导 TNBC细胞的转录低氧应激反应;2.确定BACH1是否促进血管生成, TNBC肿瘤的血管泄漏和缺氧;以及3.确定BACH1耗竭是否使TNBC增敏 肿瘤对辐射的影响。我们认为,靶向BACH1是增加肿瘤的一种独特策略 氧合以提高细胞毒性、标准护理疗法的疗效,如放射治疗。正规化 抑制渗漏的血管系统也应该促进药物向肿瘤的输送。由于BACH1可以成为目标 FDA批准的药物单独或与HIF抑制剂联合使用,拟议的工作可能导致 在乳腺癌和其他癌症患者中进行的临床试验,这些患者的治疗包括放射治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARSHA R ROSNER其他文献

MARSHA R ROSNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARSHA R ROSNER', 18)}}的其他基金

Regulation of RKIP Function
RKIP功能监管
  • 批准号:
    9218899
  • 财政年份:
    2017
  • 资助金额:
    $ 39.83万
  • 项目类别:
Regulation of RKIP Function
RKIP功能监管
  • 批准号:
    9567983
  • 财政年份:
    2017
  • 资助金额:
    $ 39.83万
  • 项目类别:
Tumor-stromal interactions as targets of tumor metastasis suppressors
肿瘤-基质相互作用作为肿瘤转移抑制因子的靶点
  • 批准号:
    8817963
  • 财政年份:
    2015
  • 资助金额:
    $ 39.83万
  • 项目类别:
Tumor-stromal interactions as targets of tumor metastasis suppressors
肿瘤-基质相互作用作为肿瘤转移抑制因子的靶点
  • 批准号:
    9223680
  • 财政年份:
    2015
  • 资助金额:
    $ 39.83万
  • 项目类别:
Modulation of Head and Neck Cancer by Protein Kinase C
蛋白激酶 C 对头颈癌的调节
  • 批准号:
    7104272
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Modulation of Head and Neck Cancer by Protein Kinase C
蛋白激酶 C 对头颈癌的调节
  • 批准号:
    7232269
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    6990554
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    7154753
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    7533439
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
Raf 激酶抑制蛋白在前列腺癌中的作用
  • 批准号:
    7322528
  • 财政年份:
    2004
  • 资助金额:
    $ 39.83万
  • 项目类别:

相似海外基金

Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
  • 批准号:
    24K18002
  • 财政年份:
    2024
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Sustainable antioxidants for industrial process fluids
SBIR 第一阶段:工业过程流体的可持续抗氧化剂
  • 批准号:
    2222215
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Standard Grant
Development of a new bone augmentation method that enables long-term survival and long-term functional expression of transplanted cells by antioxidants
开发一种新的骨增强方法,通过抗氧化剂使移植细胞能够长期存活和长期功能表达
  • 批准号:
    23K09272
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Non-Invasive Probing Cellular Oxidative Stress and Antioxidants Therapeutic Effectiveness
非侵入性探测细胞氧化应激和抗氧化剂的治疗效果
  • 批准号:
    10652764
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
线粒体靶向新型阳离子腙抗氧化剂用于治疗先兆子痫
  • 批准号:
    10730652
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Latent Antioxidants for Environmentally Responsible Polymer Formulations
用于环保聚合物配方的潜在抗氧化剂
  • 批准号:
    RGPIN-2018-04107
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Discovery Grants Program - Individual
Contribution of antioxidants to regeneration of rotator cuff insertion
抗氧化剂对肩袖插入再生的贡献
  • 批准号:
    22K16720
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of different doses of antioxidants(Vitamin E) intake on exercise induced oxidative stress, antioxidative capacity and chronic inflammation
不同剂量抗氧化剂(维生素E)摄入对运动引起的氧化应激、抗氧化能力和慢性炎症的影响
  • 批准号:
    22K11609
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Polyunsaturated fatty acid (PUFA), inflammation and antioxidants
多不饱和脂肪酸 (PUFA)、炎症和抗氧化剂
  • 批准号:
    RGPIN-2019-05674
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Discovery Grants Program - Individual
Suppressed methemoglobin formation of artificial red cell by liposomal antioxidants and its mechanism.
脂质体抗氧化剂抑制人工红细胞高铁血红蛋白形成及其机制
  • 批准号:
    22K12824
  • 财政年份:
    2022
  • 资助金额:
    $ 39.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了